Skip to content
10-Q

Quarterly Report

Compass Therapeutics, Inc. CMPX

0001171843-25-002953

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 28, 2025 138.28M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $14.9M
Current Liabilities Q1 2025 · Dec 31, 2024 $8.87M
Total Liabilities Q1 2025 · Mar 31, 2025 $21.17M
Total Liabilities Q1 2025 · Dec 31, 2024 $15.17M
Current Assets Q1 2025 · Mar 31, 2025 $124.15M
Current Assets Q1 2025 · Dec 31, 2024 $132.75M
Total Assets Q1 2025 · Mar 31, 2025 $131.45M
Total Assets Q1 2025 · Dec 31, 2024 $140.4M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $43.48M
Cash And Equivalents restated Q1 2025 · Mar 31, 2024 $43.48M
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$13.89M
Stockholders Equity Q1 2025 · Mar 31, 2024 $157.06M
Stockholders Equity Q1 2025 · Dec 31, 2023 $148.54M
Eps Basic Q1 2025 · Mar 31, 2024 −$0.08
Sga Expense Q1 2025 · Mar 31, 2024 $3.25M
Rd Expense Q1 2025 · Mar 31, 2024 $9.52M
Net Income Q1 2025 · Mar 31, 2024 −$10.79M
Operating Income Q1 2025 · Mar 31, 2024 −$12.77M